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Cylindromatosis Gene CYLD Regulates Hepatocyte
Growth Factor Expression in Hepatic Stellate Cells
Through Interaction With Histone Deacetylase 7
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Hepatic fibrosis is considered as a physiological wound-healing response to liver injury.
The process involves several factors, such as hepatocyte growth factor (HGF), which
restrains hepatic injury and facilitates reversibility of fibrotic reaction in response to an
acute insult. Chronic liver injury and sustained inflammation cause progressive fibrosis
and, ultimately, organ dysfunction. The mechanisms tipping the balance from restora-
tion to progressive liver tissue scarring are not well understood. In the present study, we
identify a mechanism in which the tumor-suppressor gene, cylindromatosis (CYLD),
confers protection from hepatocellular injury and fibrosis. Mice lacking CYLD
(CYLD2/2) were highly susceptible to hepatocellular damage, inflammation, and fibro-
sis and revealed significantly lower hepatic HGF levels, compared to wild-type (WT)
animals. Exogenous application of HGF rescued the liver injury phenotype of CYLD2/2
mice. In the absence of CYLD, gene transcription of HGF in hepatic stellate cells was
repressed through binding of histone deacetylase 7 (HDAC7) to the promoter of HGF.
In WT cells, CYLD removed HDAC7 from the HGF promoter and induced HGF
expression. Of note, this interaction occurred independently of the deubiquitinating
activity of CYLD. Conclusions: Our findings highlight a novel link between CYLD and
HDAC7, offering mechanistic insight into the contribution of these proteins to progres-
sion of liver disease. Thus, through regulation of HGF level, CYLD ameliorates hepato-
cellular damage and liver fibrogenesis. (HEPATOLOGY 2014;60:1066-1081)
H
epatic fibrosis can be considered as a physiologi-
cal wound-healing response to liver injury. The
process also engages factors, including hepatocyte
growth factor (HGF), restraining hepatic injury and facili-
tating reversibility of the fibrotic reaction in response to an
acute insult. However, chronic liver injury (CLI) and sus-
tained inflammation cause progressive fibrosis and, ulti-
mately, organ dysfunction. Activation of hepatic stellate
cells (HSCs) is a key event of hepatic fibrogenesis. Upon
activation, HSCs transdifferentiate into myofibroblasts and
produce the major fraction of extracellular matrix (ECM)
proteins during hepatic fibrogenesis.1-3 The most well-
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known profibrogenic mediators expressed by activated
HSCs include transforming growth factor beta (TGF-b)
and platelet-derived growth factor, whereas HGF functions
as an antifibrogenic mediator.2,3 Although the effects of
HGF in reducing accumulation of ECM and development
of hepatic fibrosis have been well studied, the exact mecha-
nism regulating HGF expression in HSCs in response to
liver injury and inflammation remains unknown.
CYLD is a deubiquitination enzyme acting as a tumor
suppressor in different types of cancer.4 Deubiquitin
activity of CYLD interferes with components of distinct
signaling pathways, thereby regulating different cellular
processes, such as proliferation and survival.5-7 CYLD is
down-regulated in hepatocellular carcinoma (HCC), and
forced expression of CYLD in HCC cell lines triggers a
significant decrease in nuclear factor kappa B (NF-jB)
activity.8,9 A recent study demonstrated that deletion of
CYLD exon 9 generates a deubiquitinase-deficient form
of CYLD, which causes hepatic inflammation, fibrosis,
and cancer.10 The phenotype of these mice reflects ele-
vated TGF-b1-activated kinase 1 (TAK1) ubiquitination
and Jun N-terminal kinase (JNK) activation caused by
lack of CYLD-mediated cleavage of polyubiquitin chains
from TAK1.10 Another recent study showed that deletion
of CYLD exon 7/8, a short splice variant of CYLD, leads
to biliary fibrosis and increased susceptibility for chemi-
cally induced HCC.11 Despite these important findings,
the current knowledge about the CYLD-mediated signal-
ing pathway that ameliorates hepatocellular damage and
liver fibrogenesis is limited.
Histone acetylation (HAC) is associated with active
gene transcription and histone deacetylation with tran-
scriptional repression. Acetylation status of histones is
controlled through opposing actions of two classes of
enzymes: histone acetyltransferases (HATs), which transfer
acetyl groups to lysine residues within the N-terminal tails
of core histones, and histone deacetylases (HDACs),
which remove the acetyl groups.12,13 Generally, HAC
loosens the structure of chromatin, facilitates access of the
transcriptional machinery to DNA, and initiates gene
transcription.12 In contrast, HDACs remove acetyl groups
from histone proteins and reverse the effects of HATs
through alterations in transcription.13 To date, 18 human
HDACs have been identified and grouped into four
classes. HDAC7 is a member of a class of HDACs that
shuttle between the cytoplasm and nuclei. HDAC7 sup-
presses expression of the angiogenesis suppressor gene, A
kinase anchor protein 12,14 Nuclear factor of activated
T cells, cytoplasmic 1,15 c-jun,16 and the cell-cycle inhibi-
tor gene, Reprimo.17 More recently, it was shown that
forced accumulation of HDAC7 in the nucleus of cyto-
toxic T cells suppresses expression of genes encoding cyto-
kines, cytokine receptors, and adhesion molecules.18 The
function of HDACs, including HDAC7, is blocked using
HDAC inhibitors (HDACi). These compounds interact
with the catalytic domain of HDACs and alter gene
expression. HDACi reduce expression of inflammatory
and fibrotic genes, thereby exhibiting strong antifibrotic
characteristics in the liver. In these studies, treatment with
HDACi inhibited HSC activation and reduced liver
fibrosis.19-21 However, the HDAC target of HDACi in
reducing HSC activation has not been identified.
In the present study, we observed that, upon hepatic
injury, cylindromatosis (CYLD) regulates expression of
hepatocyte growth factor (HGF) through direct interac-
tions that prevent HDAC7 recruitment to the promoter
of HGF. Elevated levels of HGF in the presence of
CYLD reduced hepatocellular death and hepatic fibrosis.
Materials and Methods
Cells and Cell Culture. Primary murine hepatocytes
and primary murine and human HSCs were isolated
and cultured as previously described.22-24 In vitro HSC
activation was achieved through cell culture on uncoated
tissue-culture dishes as previously described.23,24
Animals and Experimental Murine Models of
Hepatic Injury. Generation of CYLD KO (knock-
out; CYLD2/2) mice has previously been described.25
Mice were maintained in specific pathogen-free hous-
ing at the Clinical Research Center (Malm€o, Sweden)
and at the University Hospital Regensburg (Regens-
burg, Germany), and animal experiments were per-
formed according to national and international
guidelines of the European Union (EU). At the age of
10-12 weeks, male C57BL/6 WT (wild-type;
CYLD1/1) and CYLD2/2 mice underwent different
models of acute liver injury (ALI) and CLI (5-6 ani-
mals per group). For short-term studies of hepatocellu-
lar injury and inflammation, diethylnitrosamine
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(DEN; Sigma-Aldrich, St. Louis, MO) was intraperito-
neally (IP) injected (100 lg/g body weight [b.w.]), and
animals were sacrificed at the indicated time points.
CCl4-induced ALI was analyzed 24 hours after IP
injection of 1 lL of CCl4/g b.w. (diluted with corn
oil). Galactosamine hydrochloride (GalN) plus tumor
necrosis factor (TNF)-induced ALI were analyzed 6
hours after IP injection of 1 mg of GalN/g b.w. and
Fig. 1. CYLD2/2 mice are more susceptible to ALI than WT mice. (A) Analysis of hepatic CYLD mRNA and protein expression levels in mice
after DEN treatment for 24 hours (n5 5/group), compared to control mice. (B) Evaluation of apoptotic cells in liver using the terminal deoxynu-
cleotidyl transferase dUTP nick end labeling (TUNEL) assay in 15-day-old DEN-treated WT (n5 5) and CYLD-deficient (KO; n5 5) animals after
24 hours. (C) Quantification of serum levels of alanine aminotransferase (ALT) in DEN-treated WT and KO mice. (D) The number of CD3-positive
inflammatory cells in liver of WT and KO mice after DEN treatment for 24 hours. (F) Hepatic mRNA expression of TNF, IL-6, and IL-1 in WT and
KO mice after DEN treatment for 6 hours. *P< 0.05.
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Fig. 2. CYLD2/2 mice are more susceptible to CLI than WT mice. (A) Analysis of hepatic CYLD mRNA and protein expression in BDL and
sham-operated (sham) WT mice (n5 6/group). (B) Alanine aminotransferase (ALT) serum levels in BDL WT and KO mice. (C) Hematoxylin and
eosin staining of liver tissue sections from BDL WT and KO mice, showing marked bile duct proliferation and necrotic areas. (D) Analysis of proin-
flammatory (TNF, IL-6, and IL-1) and (E) profibrogenic (collagen type I; Coll-1) hepatic gene expression in BDL WT and KO mice. (F) Sirius Red/
fast green staining of hepatic tissue from BDL WT and KO mice and quantification of stained areas. *P< 0.05.
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0.02 lg of TNF/g b.w. (diluted with phosphate-buf-
fered saline [PBS]). In addition, bile duct ligation
(BDL) or sham operations were performed as previ-
ously described,26 and animals were sacrificed at 3
weeks after the operation. A nonalcoholic steatohepati-
tis (NASH)-inducing methionine- and choline-
deficient diet (MCD diet) or control diet was fed for
6 weeks. The MCD diet was purchased from MP Bio-
medicals (Solon, OH); all other chows were purchased
from Ssniff (Soest, Germany). To assess the effect of
recombinant HGF on DEN-mediated liver injury in
CYLD2/2 mice, a single IP injection of recombinant
murine HGF (1.68 lg/kg; R&D Systems, Abingdon,
UK) or vehicle (PBS) was administered to CYLD2/2
mice. Twenty-four hours later, an IP injection with
DEN (100 mg/kg b.w.) was administered together
with an intravenous HGF or vehicle (PBS) application.
All mice were sacrificed through heart puncture under
deep ketamine/xylazine (2:1) anesthesia, and liver tis-
sue and blood samples were collected for further
analyses.
Human Tissue Specimens. Formalin-fixed,
paraffin-embedded human liver tissues for immunohis-
tochemical (IHC) analysis were retrieved from the sur-
gical pathology files of the Institute of Pathology of
the University of Regensburg. Human liver tissue for
cell isolation and expression analyses was obtained
according to the guidelines of the charitable state-
controlled foundation, Human Tissue and Cell
Research (Regensburg, Germany). Informed consent
was obtained from all patients, and the study was
approved through the local ethics committee of the
University of Regensburg.
Statistical Analyses. Statistical analyses were per-
formed using GraphPad Prism5 software (GraphPad
Software Inc., San Diego, CA). Results are expressed
as the means6 standard error (range) or percent.
Two-tailed P values were calculated using Mann-
Whitney’s U test. A correlation analysis was per-
formed using Pearson’s product-moment correlation
coefficient. A P value <0.05 was considered statisti-
cally significant.
Additional Methods. Detailed methodology is
described in the Methods section of the Supporting
Information.
Results
CYLD Deficiency Aggravates Hepatocellular Dam-
age, Inflammation, and Fibrosis in Response to ALI
and CLI. CYLD is ubiquitously expressed in human
and murine livers (Supporting Fig. 1A), but mice lack-
ing the CYLD gene25 exhibited regular liver architec-
ture and hepatocellular integrity under physiological
conditions (Supporting Fig. 1B-E). To understand the
role of CYLD under pathophysiological conditions, we
exposed WT (CYLD1/1) and CYLD-deficient
(CYLD2/2) mice to models of ALI and CLI. The
acute toxicity of DEN or CCl4 in liver caused a
marked up-regulation of hepatic CYLD expression in
WT mice (Fig. 1A and Supporting Fig. 2). CYLD2/2
mice displayed a significantly increased number of
apoptotic cells (Fig. 1B), higher levels of serum transa-
minases (Fig. 1C), and an increased number of
recruited inflammatory cells (Fig. 1D and Supporting
Fig. 3A), compared to CYLD1/1 mice, in response to
acute hepatic injury through DEN. These results were
consistent with the enhanced levels of the proinflam-
matory genes (Fig. 1E and Supporting Fig. 3B,C) and
with multifocal areas of necrosis (Supporting Fig. 4) in
livers of DEN-treated CYLD2/2 mice. In contrast,
CYLD2/2 control mice untreated or injected with
vehicle (PBS or mineral oil) did not show any signifi-
cant differences in infiltration of inflammatory or apo-
ptotic cells, compared to WT liver tissue. In addition,
levels of serum transaminases and hepatic proinflam-
matory gene expression were similar between
CYLD2/2 and CYLD1/1 mice (Supporting Fig. 5).
To simulate chronic hepatic injury, we used 3-week
BDL, an established model of extrahepatic cholestasis
in rodents.26 Similar to the DEN and CCl4 models,
we observed a marked up-regulation of hepatic CYLD
expression in control mice (Fig. 2A). In the BDL
model, CYLD2/2 mice showed more hepatocellular
Fig. 3. CYLD expression is increased in activated HSCs, and CYLD deficiency leads to enhanced HSC activation in response to hepatic injury.
(A) Analysis of hepatic a-SMA mRNA expression in DEN-treated (left panel; n5 5/group) and BDL (right panel; n5 6/group) WT and CYLD-
deficient (KO) mice. (B) a-SMA IHC staining of hepatic tissue from BDL WT and KO mice and quantification of stained areas (*P< 0.05, com-
pared with WT). (C) Correlation analysis of CYLD and a-SMA mRNA expression levels in liver tissue from 27 patients with CLD using quantitative
polymerase chain reaction. (D) IHC staining of CYLD and a-SMA revealing strong CYLD immunosignals in a-SMA-positive cells in fibrotic septa of
cirrhotic human livers (magnification right panel: 1003). (E) IF staining of CYLD and a-SMA in hepatic tissue from patients with CLD, revealing a
strong CYLD immunosignal in a-SMA-positive cells in fibrotic septa of cirrhotic human liver. (F) Comparison of CYLD mRNA and protein expression
in quiescent (day 2) and activated (day 7) human HSCs using quantitative polymerase chain reaction and western blotting analyses (*P< 0.05,
compared with day 2). (G) Expression of CYLD mRNA (from 6 different donors) and protein in untreated (control) and TNF (10 ng/mL for 24
hours)-stimulated primary human HSCs.
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damage (Fig. 2B,C), increased levels of proinflamma-
tory genes, and inflammatory cell markers (Fig. 2D
and Supporting Fig. 6), compared to CYLD1/1 mice.
Furthermore, we applied a second model of CLI, in
which we fed mice an MCD diet, causing NASH. In
this model, CYLD deficiency did not affect triglyceride
Fig. 4.
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levels in liver and serum (Supporting Fig. 7), but exa-
cerbated hepatocellular damage and inflammation
(Supporting Fig. 8). Moreover, CLI induced higher
hepatic expression levels of profibrogenic genes (Fig.
2E and Supporting Fig. 8), and Sirius Red staining
revealed enhanced hepatic collagen deposition in
CYLD2/2, compared to CYLD1/1, mice (Fig. 2F). In
both models, CYLD2/2 and CYLD1/1 control mice
(fed with control diet or sham operated) showed simi-
lar levels of proinflammatory and -fibrogenic gene
expression, and neither CYLD2/2 nor CYLD1/1 mice
revealed significant infiltration with inflammatory or
apoptotic cells in liver (Supporting Figs. 8 and 9).
Next, we compared JNK and TAK activation in
CYLD2/2 and CYLD1/1 mice using CCl4 and GalN/
TNF treatment. We did not observe any significant
differences in JNK and TAK activation comparing
nontreated hepatocytes isolated from CYLD2/2 and
CYLD1/1 mice (Supporting Fig. 10A). In GalN/TNF-
treated liver and hepatocytes, we detected elevated
JNK activation in CYLD2/2, compared to CYLD1/1,
mice (Supporting Fig. 10B,C). Furthermore, CCl4
treatment promoted activation of TAK1 and ubiquiti-
nation of TNF receptor-associated factor 2 (TRAF2)
in CYLD2/2, compared to CYLD1/1, livers and hepa-
tocytes (Supporting Fig. 10B-E). Both GalN/TNF and
CCl4 treatment increased cell death in CYLD
2/2,
compared to CYLD1/1, hepatocytes (Supporting Fig.
10B).
CYLD Expression Is Increased in Activated
HSCs. Hepatic injury results in activation of the
HSCs, which is characterized by de novo expression of
alpha-smooth muscle actin (a-SMA).2,3 In ALI and
CLI models, enhanced hepatic a-SMA expression in
CYLD2/2 mice, compared to CYLD1/1 mice, was
reflecting more advanced HSC activation (Fig. 3A)
and IHC confirmed an increased number of a-SMA-
positive cells in chronically injured CYLD2/2, com-
pared to CYLD1/1, liver tissue (Fig. 3B). In contrast,
neither CYLD2/2 nor CYLD1/1 mice showed signifi-
cant HSC activation under nontreated conditions
(Supporting Fig. 11). Notably, a striking correlation
between CYLD and a-SMA expression was observed
in hepatic tissue from patients with chronic liver dis-
ease (CLD; Fig. 3C). IHC analysis revealed similar
CYLD-staining intensity of hepatocytes in control and
cirrhotic human liver tissues (Supporting Fig. 12), but
a strong CYLD immunosignal in a-SMA-positive cells
in fibrotic septa of cirrhotic human livers (Fig. 3D).
Double immunofluorescence (IF) analysis confirmed
colocalization of CYLD and a-SMA in cirrhotic liver
tissue (Fig. 3E). Moreover, in an in vitro model of
HSC activation, we observed that activated HSCs (day
7) expressed higher levels of CYLD than quiescent
HSCs (day 2; Fig. 3F), and CYLD expression in acti-
vated HSCs was further induced in response to TNF
stimulation (Fig. 3G). Together, these findings indi-
cated that CYLD expression is inducible during HSC
activation and in response to proinflammatory cyto-
kine stimulation.
The Functional Role of CYLD in Activated
HSCs. To obtain further insight into the role of
CYLD in HSCs, we suppressed CYLD expression in
activated human HSCs and observed that expression of
CYLD interfered with activation of the classic NF-jB
pathway (Fig. 4A) and expression of NF-jB target
genes, such as monocyte chemoattractant protein 1
(MCP-1), intracellular adhesion molecule 1 (ICAM-1),
and interleukin (IL)-6 (Fig. 4B), which are up-regulated
during HSC activation.2 In contrast, and unexpectedly,
CYLD suppression in activated HSCs reduced expres-
sion of HGF (Fig. 4C), but not expression of other
growth factors in human HSCs (Supporting Fig. 13A).
To validate these findings, we isolated HSCs from
CYLD1/1 and CYLD2/2 mice. Activation of murine
CYLD2/2 HSCs revealed enhanced expression of NF-
jB-regulated pro-inflammatory genes, compared to WT
cells (Supporting Fig. 13B) and electrophoresis mobility
shift assay analysis confirmed enhanced NF-jB binding
activity in TNF-stimulated CYLD2/2 HSCs, compared
to CYLD1/1 HSCs (Supporting Fig. 14A). In contrast,
we found no differences in activation of TAK1 and JNK
comparing CYLD2/2 and CYLD1/1 HSCs (Supporting
Fig. 14B). Liver tissues or quiescent HSCs isolated from
CYLD1/1 and CYLD2/2 mice revealed no significant
differences in HGF expression under noninduced condi-
tions (Supporting Fig. 15A,B). In contrast, hepatic HGF
expression was significantly lower in CYLD2/2 than in
Fig. 4. Reduced HGF expression in CYLD-deficient HSCs and CYLD2/2 mice in models of hepatic injury. (A) Western blotting analysis of CYLD
protein expression in human HSCs treated by TNF (10 ng/mL for 6 hours) and its suppression by transfection with CYLD-siRNA (si#1 and si#2; 4
days posttransfection). Control cells were transfected with negative control siRNA. Western blotting analyses disclosed the effects of siRNA-mediated
CYLD suppression on p65 and IjBa phosphorylation (basal or upon TNF stimulation; 10 ng/mL for 10 minutes). (B) Quantification of mRNA expres-
sion of NF-jB target genes MCP-1, ICAM-1, and IL-6 and (C) HGF in human HSCs after transfection with CYLD-siRNA (4 days posttransfection);
negative control siRNA served as the control (*P< 0.05, compared to control-siRNA). (D) Expression levels of HGF at the mRNA and (E) protein
level in livers from WT and KO mice after treatment with DEN for 6 hours (n5 6/group). (F) Quantification of HGF mRNA in activated HSCs (left
panel) and (G) HGF protein in the supernatant of activated HSCs (right panel) isolated from WT and KO mice. *P< 0.05, compared to WT.
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CYLD1/1 mice in models of DEN- or CCl4-induced
liver injury (Fig. 4D,E and Supporting Fig. 15C), simi-
lar to the HGF expression in activated HSCs isolated
from CYLD2/2 and CYLD1/1 mice (Fig. 4F,G). In
contrast, expression of other growth factors was either
similar or enhanced (Supporting Fig. 13C,D). These
data indicate CYLD as a critical regulator of HGF in
activated HSCs.
Fig. 5.
1074 PANNEM, DORN, ET AL. HEPATOLOGY, September 2014
Effect of CYLD-Mediated HGF Regulation in
Activated HSCs. Activated HSCs are the major
source of hepatic HGF, which plays a critical role in
tissue protection and regeneration and provides less
susceptibility to chronic inflammation and fibrosis.27-
30 To characterize the effect of reduced HGF expres-
sion on hepatocellular damage in CYLD-deficient
HSCs, we incubated primary hepatocytes, isolated
from CYLD1/1 mice, with conditioned medium (CM)
from activated HSCs derived from CYLD1/1 or
CYLD2/2 mice, before treatment with DEN. This
procedure promoted caspase-3/7 activity, which was
significantly higher in hepatocytes stimulated with CM
from CYLD2/2, compared with those treated with
CM from CYLD1/1 HSCs (Fig. 5A). Inhibition of
HGF downstream signaling, after addition of neutral-
izing anti-HGF antibody (Ab), enhanced DEN-
induced caspase-3/7 activity in hepatocytes treated
with CM from CYLD1/1 HSCs, but not in hepato-
cytes incubated with CM from CYLD2/2 HSCs (Fig.
5A, left panel). Conversely, supplementation with
recombinant HGF did not affect caspase-3/7 activity
in hepatocytes incubated with CM from CYLD1/1
HSCs, but alleviated DEN-induced caspase-3/7 activ-
ity in hepatocytes treated with CM from CYLD2/2
HSCs (Fig. 5A, right panel). Next, we assessed
whether exogenous HGF ameliorates hepatocellular
injury in CYLD-deficient mice. Injection of recombi-
nant HGF into CYLD2/2 mice before acute DEN-
induced hepatic injury significantly reduced hepatic
cell death (Fig. 5B), proinflammatory gene expression
(Supplorting Fig. F16A), inflammatory cell recruit-
ment (Fig. 5C), and profibrogenic gene expression
(Fig. 5D; Supporting Fig. 16B). The potent activity of
HGF in preventing cell death in distinct types of cells,
including hepatocytes, is typically mediated through
activation of protein kinase B (Akt).31-33 DEN treat-
ment markedly increased activation of Akt in
CYLD1/1, but not in CYLD2/2, hepatic tissue (Fig.
5E). Furthermore, in CYLD-deficient mice, injection
of HGF before DEN treatment elevated activation of
Akt (Fig. 5E,F). In CYLD1/1 mice, HGF application
did not significantly affect apoptosis, proinflammatory
and -fibrogenic gene expression, or Akt activation
(Supporting Fig. 17). Taken together, these results sug-
gest that lower HGF levels in CYLD-deficient mice
result in pronounced hepatic injury, inflammation, and
profibrogenic gene expression, associated with the
development and progression of hepatic injury.
CYLD Regulates HGF Levels in HSCs Through
Interaction With HDAC7. Next, we identified the
mechanisms through which CYLD induces HGF
expression in HSCs. The cytokines, IL-6 and TNF,
primarily secreted from activated Kupffer cells (KCs)
in response to hepatic injury, stimulate HGF produc-
tion in HSCs.34,35 Both cytokines promoted HGF
expression and secretion in HSCs isolated from
CYLD1/1 mice, but not in CYLD-deficient HSCs
(Fig. 6A). Furthermore, luciferase assays demonstrated
substantially increased HGF promoter activity after
CYLD transfection (Fig. 6B), indicating that CYLD
regulates expression of HGF at the transcriptional
level. HDACs balance the acetylation activities of
HACs during chromatin remodeling. HDACs are
essential in regulating gene transcription, and inhibi-
tion of these enzymes suppresses HGF expression in
tumor stroma.36 To determine whether the repression
of HGF in the absence of CYLD is dependent on his-
tone acetylation, HSCs were treated with the potent
HDACi, trichostatin A (TSA) or trapoxin (TPX). This
treatment generated an increase of HGF levels in both
WT and CYLD-deficient HSCs (Fig. 6C,D). HDAC7
is a member of the HDAC class IIa enzymes, possess-
ing nucleocytoplasmic shuttling properties.37 It was
recently shown that TNF derepresses expression of
HDAC7 target genes.38 To determine whether CYLD
regulates HDAC7 in HSCs, thereby affecting HGF
production, we overexpressed CYLD and observed that
CYLD overrode HDAC7-mediated inhibition of HGF
promoter activity (Fig. 6E) and overexpression of
HDAC7 inhibited TNF- or IL6-induced HGF expres-
sion (Fig. 6F).
Fig. 5. HGF ameliorates DEN-induced liver injury and fibrosis. (A) Caspase-3/7 activity in primary hepatocytes from WT mice, quantified using
the Apo-One Homogeneous Caspase-3/7 assay (Promega, Madison, WI). One day after isolation, hepatocytes were preincubated for 16 hours
with CM derived from TNF-stimulated (10 ng/mL for 48 hours) activated HSCs (30,000 cells/cm2 in 150 lL/cm2 serum-free Dulbecco’s modi-
fied Eagle’s medium, high glucose, for 48 hours), isolated from WT or CYLD-deficient (KO) mice, as described in the Materials and Methods sec-
tion. In addition, cells were incubated with (left panel) a neutralizing anti-mHGF Ab (AF2207; 1 lg/mL; anti-goat immunoglobulin G served as a
control; R&D Systems, Minneapolis, MN) or (right panel) with recombinant murine HGF (from PeproTech, Hamburg, Germany), as previously
described. Subsequently, apoptosis was induced through stimulation with DEN (10 mM for 16 hours). (B) The number of terminal deoxynucleoti-
dyl transferase dUTP nick end labeling (TUNEL)-positive cells, and caspase-3/7 activity in livers from WT and KO mice treated with DEN (n5 3),
or HGF and DEN (n5 3). (C) The level of inflammatory cells (CD3-positive cells) in livers of KO mice treated with DEN, or HGF and DEN. (D)
Hepatic mRNA expression of collagen type-I (Coll-1) in KO mice treated with DEN, or HGF and DEN (n5 3-6). (E) Expression of activated Akt in
livers from DEN-treated (24 hours) WT and KO mice or HGF- and DEN-treated (48 hours) KO mice. (F) IHC analysis of phospho-Akt in livers of
DEN, or HGF- and DEN-treated KO mice. *P< 0.05.
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Furthermore, IL-6 and TNF stimulation reduced
nuclear translocation of HDAC7 (Fig. 7A) and its
recruitment to the promoter of HGF (Fig. 7B) in WT,
but not in CYLD-deficient, HSCs (Fig. 7A,B). DNA
immunoprecipitation assay confirmed direct binding of
HDAC7 to the HGF promoter (Supporting Fig. 18).
Most important, knocking down HDAC7 expression
using small interfering RNA (siRNA) or short hairpin
RNA resulted in elevated levels of HGF messenger
RNA (mRNA) in both CYLD1/1 and CYLD2/2
HSCs (Fig. 7C). In addition, overexpression of the
shuttling-deficient HDAC7 mutant (HDAC7-mNES)
prevented induction of HGF in CYLD1/1 HSCs (Fig.
7D). Thus, interaction of CYLD with HDAC7 in the
cytoplasm in response to IL-6 or TNF stimulation
might reflect reduced nuclear translocation and recruit-
ment to the HGF promoter. Endogenous immunopre-
cipitation and colocalization studies showed that, in
nonstimulated CYLD1/1 HSCs, HDAC7 was primar-
ily localized in nuclei, whereas stimulation with TNF
promoted translocation of HDAC7 from the nucleus
to the cytoplasm (Fig. 7E, upper panels). In contrast,
HDAC7 was constitutively localized in the nucleus of
CYLD2/2 HSCs in the absence or presence of TNF
(Fig. 7E, lower panels). Furthermore, intense cytoplas-
mic colocalization (Fig. 7E) and an association (Fig.
7F) between HDAC7 and CYLD were detected in
stimulated cells. However, total levels of HDAC7 did
not differ between nonstimulated and stimulated cells
(Fig. 7F).
Overexpression of a catalytic mutant version of
CYLD (CYLD-C/S) blocked HDAC7 nuclear localiza-
tion, suggesting that deubiquitinating activity of
CYLD is not responsible for blocking the nuclear
localization of HDAC7 after IL-6 or TNF stimulation
(Fig. 8A). Furthermore, FLAG pull-down assays, using
a series of CYLD deletion mutants, showed that a con-
struct containing the third CAP-Gly domain and the
proline-rich region of CYLD (CYLD 222-956) inter-
acted with purified HDAC7 (Fig.8 B,C). These results
suggest that IL-6 and TNF promote the binding of
HDAC7 to CYLD while blocking nuclear transloca-
tion and recruitment of HDAC7 to the HGF pro-
moter. However, in the absence of CYLD, HDAC7
mediates the down-regulation of HGF expression,
which promotes hepatocellular damage, inflammation,
and fibrosis in response to hepatic injury.
Discussion
Deubiquitination is a highly regulated process
implicated in different signaling pathways, and muta-
tions in several deubiquitination enzymes have been
linked to acute and chronic inflammatory diseases.
CYLD is a deubiquitination enzyme acting as a tumor
suppressor in different types of human cancer, includ-
ing HCC.8,39 CYLD has previously been shown to
affect mechanisms associated with acute and chronic
hepatic injury.10,11 In these studies, mice with a
hepatocyte-specific expression of a deubiquitinase-
deficient form of CYLD or mice with deletion of
CYLD’s TRAF2-binding site (exon 7/8 deleted) suf-
fered from hepatic inflammation, fibrosis, and cancer
through uncontrolled TAK1 and JNK activation.10,11
In contrast to these findings, complete deletion of
CYLD in the present study did not affect the number
of apoptotic cells, liver damage, or inflammation under
noninducing conditions. These phenotypic differences
may be explained by CYLD deletion being complete
in our study while only partial in previous studies.10,11
Here, we have uncovered a novel mechanism by which
CYLD expression in HSCs protects from hepatic
injury independently of its deubiquitin activity.
An underlying cause of the hepatoprotective and
antifibrogenic effects of CYLD is the regulatory func-
tion of this protein on HGF, a pleiotropic signaling
molecule expressed and secreted through activated
HSCs. Especially in injured liver tissue, activation of
HGF is promoted by factors secreted from hepato-
cytes, which further protects hepatocytes from cellular
damage and inhibits hepatic fibrosis.40-42 Hepatic
HGF expression was significantly lower in CYLD2/2
than in CYLD1/1 mice upon hepatic injury, and exog-
enous application of HGF rescued the liver injury
Fig. 6. CYLD regulates HGF levels in HSCs through interaction with HDAC7. (A) Expression of HGF mRNA in untreated (Ctrl), IL-6- (25 ng/mL
for 12 hours), and TNF (10 ng/mL for 12 hours)-treated primary HSCs isolated from WT (white bars) and CYLD2/2 (black bars) mice. (B) HGF
luciferase promoter activity in human HSCs transfected full-length CYLD. HSCs were transfected with pGL-2-HGF-1029 luciferase promoter con-
struct (200 ng/well) alone, or pGL-2-HGF-1029 (200 ng/well) and FLAG-CYLD (20 or 500 ng/well) for 24 hours. (C) Levels of HGF in superna-
tants from human HSCs, before and after treatment with TSA (5 ng/mL) or TPX (2 ng/ml) for 24 hours. (D) HGF mRNA levels in CYLD1/1 HSCs
(white bars) and CYLD2/2 HSCs (black bars) before and after treatment with TSA or TPX for 24 hours. (E) HGF promoter activity in human
HSCs, transfected with HDAC7 (250 or 750 ng/well) and full-length CYLD (500 ng/well) after 24 hours (upper panel). Lower panel shows levels
of CYLD and HDAC7 protein in transfected cells. (F) HGF expression at the mRNA level in mock- or HA-HDAC7-transfected (9 lg expression plas-
mid) WT HSCs in the absence (Ctrl) or presence of TNF (10 ng/mL for 48 hours, upper panel) or IL-6 (25 ng/mL for 48 hours, lower panel)
*P< 0.05, compared to control.
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phenotype observed in CYLD-deficient mice. This
treatment resulted in reduced hepatic cell death and
elevated activation and phosphorylation of Akt. In this
pathway, cell survival by HGF is mediated through sig-
naling from its receptor, c-Met, to phosphatidylinositol
3-kinase and the phosphorylation of Akt.43 Akt, in
turn, exerts antiapoptotic effects through phosphoryla-
tion of B-cell lymphoma 2–associated death promoter
and procaspase-9, which promotes cell survival.31-33
Taken together, these results suggest that CYLD-
induced HGF production inhibits hepatic injury and
cell death associated with development and progression
of hepatic fibrosis.
As a mechanism through which CYLD induces
HGF expression in HSCs, we identified the interaction
of HGF with HDAC7. HDAC7 belongs to the
Fig. 7. Proinflammatory
mediators promote interac-
tion of CYLD with HDAC7.
(A) The level of HDAC7 in
the nucleus of untreated
(control), IL-6- (25 ng/mL
for 24 hours), and TNF (10
ng/mL for 24 hours)-treated
WT HSCs (upper panel) and
CYLD2/2 HSCs (lower
panel). (B) Chromatin immu-
noprecipitation (IP) of HGF
promoter in control, IL-6-
(25 ng/mL for 24 hours),
and TNF (10 ng/mL for 24
hours)-stimulated WT HSCs
(upper panel) and CYLD2/2
HSCs (lower panel). (C)
Upper panel: Levels of
HDAC7 protein in CYLD1/1
HSCs, treated with HDAC7-
specific siRNA for 48 hours
using two different siRNA-
oligos, and in control HSCs
(untreated). Lower panel:
Expression of HGF mRNA in
CYLD2/2 HSCs transfected
with control or shHDAC7
(100 ng/mL) plasmid for 24
hours (n5 3). (D) Expres-
sion of HGF mRNA in WT
HSCs transfected with 9 lg
of green fluorescent protein
(GFP)-HDAC7 or mutant
GFP-HDAC7-mNES for 48
hours (n5 3). (E) Localiza-
tion of HDAC7 (green) and
CYLD (red) in CYLD1/1
HSCs (upper panel) and
CYLD2/2 HSCs (lower
panel), in the absence or
presence of 10 ng/mL of
TNF for 24 hours, using con-
focal IF microscopy. (F)
Endogenous immunoprecipi-
tation (IP), using CYLD Ab in
IL-6- (25 ng/mL) or TNF (10
ng/mL)-treated (24 hours),
and control (untreated)
CYLD1/1 HSCs. *P< 0.05.
IgG, immunoglobulin G; DAPI,
40,6-diamidino-2-phenylindole.
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Fig. 8. CYLD deubiquitinase activity is not responsible for blocking the nuclear localization of HDAC7. (A) Analysis of subcellular colocaliza-
tion of endogenous HDAC7 in HA-CYLD-FL (HA-tagged full-length WT CYLD) or HA-CYLD-C/S (HA-tagged catalytically mutant CYLD) transfected
primary CYLD2/2 HSCs. (B) In vitro pull-down assay, using His-HDAC7 and either full-length CYLD (CYLD-WT) or deletion of mutants of CYLD
(CYLD 1-212, CYLD 222-956, or CYLD 587-956). (C) Schematic presentation of WT CYLD and truncation mutants of CYLD. The three CAP-Gly
domains are depicted in red, proline-rich domains in gray, and the UCH domain in green. (D) Model of the up-regulation of HGF in HSCs by
inactivation of HDAC7 through CYLD, which further protects hepatocytes against injury and inhibits hepatic fibrosis. DAPI, 4’,6-diamidino-2-
phenylindole.
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HDAC class IIa enzymes, possessing nucleocytoplasmic
shuttling properties.37 It was shown recently that 14-3-
3 and Ca21/calmodulin-dependent kinase (CaMK) I
control the subcellular localization of HDAC-7.
CaMK I–mediated phosphorylation of HDAC7 stimu-
lates HDAC7 export from the nucleus, and in the
cytoplasm, HDAC7 directly interacts with 14-3-3 pro-
teins, leading to the derepression of HDAC7 target
genes.37 Here, we showed that deletion of the
HDAC7 gene in HSCs increased levels of HGF. In
contrast to WT HSCs, knockdown of CYLD did not
change HGF levels in HDAC7-deficient HSCs, indi-
cating the importance of CYLD-HDAC7 interaction
for regulation of HGF expression in HSCs. We
observed that HDAC7 was primarily localized in
nuclei of HSCs, whereas stimulation with TNF or IL-
6 promoted translocation of HDAC7 from the nucleus
to the cytoplasm and binding to CYLD. This interac-
tion further prevented the nuclear translocation of
HDAC7 and recruitment to the HGF promoter. Con-
sistent with this finding, it has recently been shown
that TNF derepressed expression of HDAC7 target
genes.38 However, it has yet to be determined whether
HDAC7 phosphorylation and binding to 14-3-3 are
necessary for CYLD interaction. However, we observed
a direct interaction between purified CYLD and
HDAC7 protein in vitro, suggesting an alternative
mechanism of HDAC7 inactivation in the cytoplasm
induced through CYLD, independent of HDAC7
phosphorylation and 14-3-3 interaction.
In summary, our findings highlight a novel link
between CYLD and HDAC7, offering mechanistic
insight into the contribution of these proteins to the
progression of liver disease. Notably, interaction between
CYLD and HDAC7 occurs independently of the deubi-
quitin activity of CYLD and functions in the presence
of proinflammatory cytokines secreted from infiltrating
inflammatory cells, resident macrophages, and HSCs,
activated in response to liver injury. We propose a
model in which CYLD-regulated hepatic HGF expres-
sion plays a crucial role in the interaction of hepatocytes
with nonparenchymal liver cells and (infiltrating)
inflammatory cells, providing protection against hepato-
cellular injury and inflammation and, consequently, the
development and progression of hepatic fibrosis (Fig.
8D). We propose that this CYLD-regulated pathway
works together with other important signaling pathways
in HSCs and other cell types, including hepatocytes,
KCs, and recruited inflammatory cells for restraining
hepatic injury and fibrosis.
In addition, the novel CYLD-HDAC7 connection
might be critical for other biological processes, consid-
ering the pleiotropic function of this HDAC under
physiological and pathological conditions. Thus, these
findings provide an avenue for potential strategies to
selectively affect HDAC7 under inflammatory condi-
tions, in CLDs, and, potentially, in conditions beyond
hepatic disorders.
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